Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 182Neoplasms 115Prostatic Neoplasms 103Multiple Myeloma 85Glioblastoma 82Pancreatic Neoplasms 75Glioma 65Brain Neoplasms 60Lung Neoplasms 58Head and Neck Neoplasms 57Melanoma 54Colorectal Neoplasms 54Carcinoma, Non-Small-Cell Lung 53Leukemia, Myeloid, Acute 51Carcinoma, Hepatocellular 50Squamous Cell Carcinoma of Head and Neck 46Recurrence 46Ovarian Neoplasms 45Lymphoma 39Lymphoma, Non-Hodgkin 37Lymphoma, B-Cell 36Sarcoma 35Stomach Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 33Solid Tumor 31Hematologic Neoplasms 31Carcinoma, Renal Cell 30Polycystic Ovary Syndrome 27Burkitt Lymphoma 27

Interventions

sacituzumab govitecan 1pembrolizumab 1erdafitinib 1enfortumab vedotin 1avelumab 1Vinblastine 1Paclitaxel 1Nivolumab 1Methotrexate 1Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × Muscle Invasive Bladder Urothelial Carcinoma × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡